Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2004; 92(04): 791-796
DOI: 10.1160/TH03-10-0618

Blood Coagulation, Fibrinolysis and Cellular Haemostasis

Schattauer GmbH

Low molecular weight heparin (tinzaparin) therapy for moderate risk thromboprophylaxis during pregnancy

A pharmacokinetic study

Lucy A. Norris

¹Coagulation Research Laboratory, Department of Obstetrics and Gynaecology, Trinity Centre for Health Sciences, St. James’s Hospital and Coombe Women’s Hospital, Dublin, Ireland

²Chelsea and Westminster Hospital and The Haemophilia Reference Centre, St. Thomas Hospital, London, UK

,

John Bonnar

¹Coagulation Research Laboratory, Department of Obstetrics and Gynaecology, Trinity Centre for Health Sciences, St. James’s Hospital and Coombe Women’s Hospital, Dublin, Ireland

²Chelsea and Westminster Hospital and The Haemophilia Reference Centre, St. Thomas Hospital, London, UK

,

Mark P. Smith

¹Coagulation Research Laboratory, Department of Obstetrics and Gynaecology, Trinity Centre for Health Sciences, St. James’s Hospital and Coombe Women’s Hospital, Dublin, Ireland

²Chelsea and Westminster Hospital and The Haemophilia Reference Centre, St. Thomas Hospital, London, UK

,

Philip J. Steer

¹Coagulation Research Laboratory, Department of Obstetrics and Gynaecology, Trinity Centre for Health Sciences, St. James’s Hospital and Coombe Women’s Hospital, Dublin, Ireland

²Chelsea and Westminster Hospital and The Haemophilia Reference Centre, St. Thomas Hospital, London, UK

,

Geoff Savidge

¹Coagulation Research Laboratory, Department of Obstetrics and Gynaecology, Trinity Centre for Health Sciences, St. James’s Hospital and Coombe Women’s Hospital, Dublin, Ireland

²Chelsea and Westminster Hospital and The Haemophilia Reference Centre, St. Thomas Hospital, London, UK

› Author Affiliations

Summary

Low molecular weight heparin (LMWH) is used increasingly for prophylaxis and treatment of venous thromboembolism during pregnancy. However, the prophylactic dose for patients at moderate risk varies between centers, and the recommended LMWH dose for the non pregnant patient is frequently used in pregnant women. The aim of this study was to investigate the effects of pregnancy on the pharmacokinetics of anti-Xa levels during moderate risk thromboprophylaxis with the LMWH, tinzaparin. In 24 pregnant women, one of three doses of tinzaparin (50, 75 or 100 IU/kg) were given according to the treating physician’s assessment of their risk profile. Four-hour peak anti-Xa levels were measured throughout pregnancy and 24-hour profiles were measured at 28 and 36 weeks gestation. Doses were adjusted when peak anti-Xa levels fell below 0.1 IU/ml and, in some cases, when levels at 10 and 18 hours post injection were undetectable (<0.05 IU/ml). Our results showed that women receiving tinzaparin (50 IU/kg) frequently had peak (4 hour) anti-Xa levels below 0.1IU/ml and that 46% of these patients required dose adjustment. Similarly anti-Xa levels were also found to be low over the 24-hour period. A starting dose of 75 IU/kg, once daily, gave greater anti-Xa cover over the 24-hour period and may avoid the need for dose adjustment. The results suggest that the pharmacokinetics of tinzaparin are affected by pregnancy. Larger studies are required to determine whether an increased tinzaparin dose (75 IU/kg) would be more effective in the prevention of thrombosis during pregnancy than 50 IU/kg

Keywords

Keywords

Clinical trials - heparins / LMWH - deep vein thrombosis - familial thrombosis

References
1 Greer IA. Thrombosis in pregnancy: maternal and fetal issues. Lancet 1999; 353: 1258-65.
2 Bonnar J. Venous thromboembolism and pulmonary embolism. In: Turnbull’s Obstetrics. Third edition. Chamberlain G, Steer PJ. Eds. Churchill Livingstone; London: 2001: 671-80.
3 Pabinger I, Grafenhofer H, Kyrle PA. et al. Temporary increase in the risk of recurrence during pregnancy in women with a history of venous thromboembolism. Blood 2002; 100 (03) 1060-2.
4 Hull RD, Raskob GE, Brant RF. et al. Low molecular weight heparin vs heparin in the treatment of patients with pulmonary embolism. Arch Intern Med 2000; 160: 229-36.
5 Sanson BJ, Lensing AWA, Prins MH. et al. Safety of low-molecular-weight heparin in pregnancy – a systematic review. Thromb Haemost 1999; 81: 668-72.
6 Lepercq J, Conard J, Borel-Derlon A. et al. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. Br J Obstet Gynecol 2001; 108: 1134-40.
7 Ellison J, Walker ID, Greer IA. Antenatal use of enoxaparin for prevention and treatment of thromboembolism during pregnancy. Br J Obstet Gynecol 2000; 107: 1116-21.
8 Brenner B, Hoffman R, Blumenfeld Z. et al. Gestational outcome in thrombophilic women treated for recurrent pregnancy loss. Thromb Haemost 2000; 83 (05) 693-7.
9 Dulitzki M, Pauzner R, Langevitz P. et al. Low molecular weight heparin during pregnancy and delivery: preliminary experience with 41 pregnancies. Obstet Gynecol 1996; 87: 380-3.
10 Samama MM, Poller L. Contemporary laboratory monitoring of low molecular weight heparins. Clin Lab Med 1995; 15 (01) 119-23.
11 Bates SM, Ginsberg JS. How we manage venous thromboembolism during pregnancy. Blood 2002; 100: 3470-8.
12 Liezorovicz A, Picolet H, Peyrieux JC. et al. Prevention of perioperative deep vein thrombosis in general surgery: a multicentre double blind study comparing two doses of Logiparin and standard heparin. Br J Surg 1991; 78: 412-16.
13 Planes A, Samama MM, Lensing AWA. et al. Prevention of deep vein thrombosis after hip replacement. Comparison between two low molecular weight heparins, tinzaparin and enoxaparin. Thromb Haemost 1999; 81: 22-25.
14 Hull R, Raskob G, Pineo G. et al. A comparison of subcutaneous low molecular weight heparin with warfarin sodium for prophylaxis against deep vein thrombosis after hip or knee implantation. N Engl J Med 1993; 329: 1370-6.
15 Smith MP, Norris LA, Steer PJ. et al. Tinzaparin sodium for thrombosis treatment and prevention during pregnancy. Am J Obstet Gynecol 2004; 190 (02) 495-501.
16 Fossler MJ, Barret JS, Hainer JW. et al. Pharmacodynamics of intravenous and subcutaneous tinzaparin and heparin in healthy volunteers. Am J Health Syst Pharm 2001; 58 (17) 1614-21.
17 Weitz JI. Low molecular weight heparins. N Engl J Med 1997; 337: 688-98.
18 Eldor A. The use of low-molecular-weight heparin for the management of venous thromboembolism in pregnancy. Eur J Obstet Gynecol Reprod Biol 2002; 104: 3-13.
19 Pauzner R, Dulitski M, Langevitz P. et al. Low molecular weight heparin and warfarin in the treatment of patients with antiphospholipid syndrome during pregnancy. Thromb Haemost 2001; 86: 1379-84.
20 Sephton V, Farquharson RG, Topping J. et al. A longitudinal study of maternal dose response to low molecular weight heparin in pregnancy. Obstet Gynecol 2003; 101 (06) 1307-11.
21 Dahlman TC, Hellgren MSE, Blomback M. Thrombosis prophylaxis in pregnancy with use of subcutaneous heparin adjusted by monitoring heparin concentration in plasma. Am J Obstet Gynecol 1989; 161: 420-5.
22 Toglia MR, Weg JG. Venous thromboembolism during pregnancy. N Engl J Med 1996; 335 (02) 108-14.
23 Casele HL, Laifer SA, Woelkers DA. et al. Changes in the pharmacokinetics of the low molecular weight heparin enoxaparin sodium during pregnancy. Am J Obstet Gynecol 1999; 05: 1113-7.
24 Jacobsen AF, Qvigstad E, Sandset PM. Low molecular weight heparin (dalteparin) for the treatment of venous thromboembolism in pregnancy. Br J Obstet Gynecol 2003; 110: 139-44.
25 Bonnar J, Green R, Norris L. Inherited thrombophilia and pregnancy: the obstetric perspective. Semin Thromb Haemost 1998; 24: 49-53.
26 Blombäck M, Bremme K, Hellgren M. et al. Thromboprophylaxis with low molecular mass heparin, “Fragmin” (dalteparin) during pregnancy – a longitudinal safety study. Blood Coagul Fibrinolysis 1998; 09: 1-9.
27 Ellison J, Thomson AJ, Conkie JA. et al. Thromboprophylaxis during caesarean section. A comparison of the antithrombotic properties of three low molecular weight heparins- dalteparin, enoxaparin and tinzaparin. Thromb Haemost 2001; 86: 1374-8.